DNA-based colon cancer test backed by U.S. advisers

the Oncology Nurse Advisor take:

An outside panel of experts advising the FDA gave their unanimous recommendation for the use of a colon cancer screening method that examines DNA samples taken from patient stool samples. The test detected 92.3 percent of colorectal cancers in average-risk patients in a large clinical trial and may be preferable in instances to traditional colonoscopy, which, although accurate, is a test avoided by many.